Search
Salacetamide
go.drugbank.com/drugs/DB20217InvestigationalSalacetamide is under investigation in clinical trial NCT00220285 (Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma).
Itruvone
go.drugbank.com/drugs/DB21543InvestigationalItruvone is under investigation in clinical trial NCT02322086 (A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10).
Taragarestrant
go.drugbank.com/drugs/DB21574InvestigationalTaragarestrant is under investigation in clinical trial NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer).
Talnetant
go.drugbank.com/drugs/DB06429Investigationalantipsychotic drug for the treatment of schizophrenia. … Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential
Ethanolamine
go.drugbank.com/drugs/DB03994InvestigationalIt is used as a surfactant, fluorimetric reagent, and to remove CO2 and H2S from natural gas and other gases.
D2C7 immunotoxin
go.drugbank.com/drugs/DB17540InvestigationalD2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.
Isaralgagene civaparvovec
go.drugbank.com/drugs/DB16808InvestigationalIsaralgagene civaparvovec, formerly known as ST-920, is liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase A (α-Gal A) enzyme.
EGT-201
go.drugbank.com/drugs/DB17648ExperimentalEGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene.
Difloxacin
go.drugbank.com/drugs/DB11511ExperimentalVet approvedHowever, it presents a reduced efficacy when compared to other fluoroquinolone antibacterials.
Zastumotide
go.drugbank.com/drugs/DB14926InvestigationalIt is under investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck).